HSD3B1 and neoplasm: An ongoing clinical trial (NCT05183828) is evaluating whether the HSD3B1 germline variant influences tumor proliferation markers, hormone receptor expression, and letrozole response in postmenopausal women with ER + HER2- BC [23].